JTJacques Thèze

Jacques Thèze

*This is an algorithmically generated author record based on publicly available information.

Jacques Thèze has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Louis Moreau

    Unite ´d'Immunoge ´ne ´tique Cellulaire De ´partement de Me ´decine Mole ´culaire Institut Pasteur 25-28, rue du Dr. Roux 75724 Cedex 15 Paris France

    4 shared publications
  • Bertrand Dupont

    Hôpital Necker, Paris, France

    3 shared publications
  • Benoît Vingert

    Univ Paris Est Creteil, INSERM, IMRB, Creteil, France

    2 shared publications
  • Christophe Demaison

    Unité d’Immunogénétique Cellulaire, Institut Pasteur , Paris

    2 shared publications
  • Denis David

    Unité d'Immunogénétique Cellulaire, Département d'Immunologie, Institut Pasteur, Paris, France

    2 shared publications
  • Franck Gesbert

    Unité d'Immunogénétique Cellulaire, Département de Médecine Moléculaire, Institut Pasteur, 25-28, rue du Dr. Roux, 75724 Paris Cedex 15, France

    2 shared publications

Latest Publications

  • HIV controllers: A multifactorial phenotype of spontaneous viral suppression

    by Jacques Thèze, Lisa A. Chakrabarti, Benoît Vingert, Filippos Porichis, Daniel E. Kaufmann


    • 1 March 2011
      • Vol. 195  (3) , 545

    [Role of CD4 lymphocytes in the efficient immune response of HIV controllers].

    by Jacques Thèze, Lisa Chakrabarti, Benoît Vingert, Olivier Lambotte, Jean-François Delfraissy

    More than 30 million people are infected by HIV worldwide. The rate of progression to AIDS is variable. A newly identified category of patients, so-called HIV controllers, spontaneously control HIV replication for long periods. HIV controllers are defined as infected patients whose viral load remains below 400 RNA copies/ml of blood, without treatment, for at least five years. We have studied the immune system of these patients, and particularly their CD4 lymphocytes, that participate in the induction, intensity, quality and duration of immune responses. CD4 lymphocytes in patients who progress to AIDS are directly targeted by the virus and participate in the activation that leads to immune deficiency. Central memory CD4 cells exhibit unusual properties in HIV controllers. Apart from the fact that they persist in large numbers and secrete large amounts of interleukin-2, which serves as an autocrine factor for their own growth, central memory CD4 cells overexpress the CCR7 homing molecule that allows them to leave capillaries and rapidly enter lymph nodes, the site of effective immune responses. These CD4 lymphocytes also men multiply rapidly, and some of them express receptors with very high antigen avidity. The presence of these central memory CD4 cells and their characteristic properties may explain the remarkable stability observed in HIV controllers. We suspect that these lymphocytes react very rapidly and efficiently to any breakthrough in viral replication. The putative relationship between HIV controllers and patients who remain asymptomatic and uninfected despite repeated exposure to the virus is discussed. Our new findings should help to guide antiretroviral therapy and vaccination strategies.

  • Lespatients” VIHcontrôleurs “:rôledeslymphocytes T CD4 dans la stimulation d’une réponse immunitaire efficace

    by Jacques Thèze, Lisa Chakrabarti, Benoît Vingert, Olivier Lambotte, JeanFrançois Delfraissy


    • 1 October 2008
      • Vol. 192  (7) , 1453

    [CD4 lymphocytes as targets and actors in the pathogenesis of HIV infection--therapeutic implications].

    by Jacques Theze

    CD4 T lymphocytes play a central role in the pathogenesis of human immunodeficiency virus (HIV) infection. In viremic patients, these cells are direct targets for the virus: HIV multiplies intensely in this subpopulation during the acute phase of the disease and continues to propagate in these same cells during the clinical latency phase. Uninfected CD4 T lymphocytes are also indirectly affected during this second phase: they are activated, become anergic, then disappear by apoptosis, ultimately contributing to CD4 lymphopenia. Our studies have shown that dysfunction of the interleukin-2 system and its receptors largely explain the early immune deficiency seen in viremic patients. Later, blockade of the homeostatic interleukin-7/CD4 loop contributes to rendering this CD4 lymphopenia irreversible. Our studies suggest that the inflammatory reaction which accompanies this infection gives rise to a state of abnormal activation, with receptor desensitization to the main cytokines regulating CD4 lymphocyte functions and numbers. In the few rare patients who manage to control HIV in the absence of any treatment, the CD4 T cell compartment has a very characteristic configuration. We have shown that an extensive subpopulation of "central memory" CD4 T lymphocytes expresses large quantities of the CCR7 homing receptor and that this helps drive these lymphocytes to infected lymph nodes. Also, these "central memory" CD4 T lymphocytes produce large quantities of IL-2, that they use in an autocrine manner, stimulating their self-renewal and ensuring their long-term survival. Our studies have opened the door to cytokine-based immunotherapy and to the development of new drug- and vaccine-based strategies.


  • Open Access

    Systemic administration of interleukin‐2 inhibits inflammatory neutrophil migration: role of nitric oxide

    by Susana E Moreno, José C Alves‐Filho, Giuliana Bertozi, Tais M Alfaya, Jacques Thèze, Sergio H Ferreira, Bernardo Boris Vargaftig

    1 Interleukin‐2 (IL‐2) has proinflammatory properties that limit its therapeutic use. Its side effects are mainly explained by the induction of a vascular leakage syndrome. Cytokines, as TNF‐α and IL‐1β, and nitric oxide (NO) generated by IL‐2‐activated leukocytes play a role in this defect. 2 As the systemic release of these mediators inhibits neutrophil migration to a specific inflammatory site, we investigated now whether IL‐2 administrated systemically inhibits the neutrophil recruitment to the inflamed peritoneum. The involvement of NO in the process was also addressed. 3 Using peritoneal neutrophils, we show that the intravenous treatment of the mice with IL‐2 inhibits the neutrophil migration induced by carrageenin, LPS or fMLP. In confirmation, IL‐2‐treated mice showed a significant reduction in leukocyte rolling and adhesion in mesenteric microcirculation evaluated after carrageenin, LPS and fMLP injections. Aminoguanidine prevented the inhibitory effect of IL‐2 on carrageenin‐induced neutrophil migration, rolling and adhesion. In contrast, IL‐2 failed to reduce the lung leukocyte infiltration induced by LPS. Therefore, IL‐2 inhibition of neutrophil migration is organ specific. 4 Our results indicate that IL‐2 administered systemically inhibits neutrophil recruitment to some inflammatory sites through a mechanism dependent on NO. The results also reinforce the needs to determine the mechanism by which patients treated with IL‐2 show increased risks of infection. British Journal of Pharmacology (2006) 148, 1060–1066. doi:10.1038/sj.bjp.0706835


  • CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients − reversal by highly active anti-retroviral therapy (HAART)

    by J.‐H. Colle, J.‐L. Moreau, A. Fontanet, O. Lambotte, M. Joussemet, J.‐F. Delfraissy, J. Thèze

    Summary: HIV infection activates abnormally the immune system and the chronic phase is accompanied by marked alterations in the CD8 compartment. The expression of CD127 (IL-7R alpha chain) by memory CD8 T lymphocytes in HIV-infected patients is analysed and reported. The memory CD8 T cell subset was characterized by expression of CD45RA and CD27 markers, and CD127 cell surface expression was measured ex vivo by four-colour flow cytometry. HIV infection was associated with a fall in the proportion of CD127+ cells among memory CD8 lymphocytes that resulted in a higher CD127– CD45RA–CD27+ CD8 T cell count in HIV-infected patients. Diminished CD127 cell surface expression [mean fluorescence intensity (MFI)] by positive cells was also observed in this subset. The data suggest that these defects were reversed by highly active anti-retroviral therapy (HAART). The regulation of CD127 expression was also studied in vitro. Down-regulation of CD127 by interkeukin (IL)-7 was observed in memory CD8 lymphocytes from healthy donors and HAART patients. Expression of CD127 by memory CD8 lymphocytes cultured in the absence of IL-7 confirmed that IL-7R regulation is altered in viraemic patients. Under the same experimental conditions, memory CD8 lymphocytes from HAART patients were shown to express CD127 at levels comparable to cells from healthy individuals. Altered CD127 cell surface expression and defective CD127 regulation in the memory CD8 T lymphocytes of HIV-infected patients are potential mechanisms by which these cells may be impeded in their physiological response to endogenous IL-7 stimulatory signals. Our data suggest that these defects are reversed during the immune reconstitution that follows HAART.


  • Open Access

    IL-2 Responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rβ transgenic mice

    by Franck Gesbert, Jean-Louis Moreau, Jacques Thèze

    Responsiveness to IL-2 varies from one lympho-mononuclear subset to another. NK lymphocytes and monocytes spontaneously respond to IL-2 whereas it is generally accepted that T and B lymphocytes need to be activated to fully acquire this competence. To further investigate this phenomenon, we studied human IL-2Rβ (hIL-2Rβ) transgenic mice constitutively expressing heterospecific, intermediate-affinity IL-2R (hIL-2Rβ/mouse IL-2Rγc). We noted that the B lymphocytes and monocytes from spleens of these hIL-2Rβ transgenic animals failed to grow when cultured in IL-2-containing medium. Under the same experimental conditions, CD4 lymphocytes survived, again without growth, whereas CD8 lymphocytes and NK cells were able to proliferate and develop potent LAK cytotoxicity. The properties of these CD4 and CD8 lymphocytes were then compared after purification. Both subsets expressed functional IL-2R able to induce global protein phosphorylation and, more precisely, signal transducer and activation of transcription 5 and Erk phosphorylation. Therefore, the differential growth potential of these CD4 and CD8 lymphocytes cannot be explained by the lack of IL-2R-dependent early signaling events. When the entrance of purified CD4 and CD8 lymphocytes into the cell cycle was analyzed, we found that the CD4 lymphocytes were unable to enter the G1 phase in the absence of anti-CD3 stimulation. This correlates with the effect of IL-2 on cyclin-dependent kinase inhibitor p27kip1. In CD4 lymphocytes, IL-2 does not affect p27kip1 expression. But in CD8 lymphocytes, IL-2 down-modulates p27kip1. These results indicate that, aside from IL-2R expression and function, IL-2 responsiveness is also controlled by lineage-specific mechanisms.


  • Human immunodeficiency virus-1 envelope glycoproteins and anti-CD4 antibodies inhibit interleukin-2-induced Jak/STAT signalling in human CD4 T lymphocytes

    by M. Kryworuchko, V. Pasquier, J. Thèze

    Summary: Human immunodeficiency virus (HIV) infection leads to a profound T cell dysfunction well before the clinical onset of acquired immunodeficiency syndrome (AIDS). We have been accumulating evidence that one of the mechanisms responsible for this T cell deficiency may be the dysregulation of signal transduction via the interleukin (IL)-2/IL-2 receptor (R) complex. In CD4 T cells, we have observed previously that viral envelope (env) glycoproteins induce IL-2 unresponsiveness and the down-regulation of the three chains making up the IL-2R (α, β, γ) in vitro. We have now established further that this disruption of the IL-2/IL-2R system manifests itself in defective signal propagation via the Janus kinase (Jak)/signal transducer and activator of transcription (STAT) pathway in response to IL-2. The treatment of CD4 T cells with HIV env or surface ligation of CD4 with anti-CD4 monoclonal antibodies inhibited the IL-2-induced activation of Jak-1 and Jak-3, as well as their targets, STAT5a and STAT5b. This Jak/STAT deficiency may contribute to the crippling of CD4 T cell responses to a cytokine central to the immune response by HIV.


  • Open Access

    Rapid Effect of Interleukin?2 Therapy in Human Immunodeficiency Virus–Infected Patients whose CD4 Cell Counts Increase Only Slightly in Response to Combined Antiretroviral Treatment

    by Denis David, Lella Naït‐Ighil, Bertrand Dupont, Jean Maral, Bertrand Gachot, Jacques Thèze

    Combined antiretroviral treatment in some human immunodeficiency virus–infected persons does not lead to a rapid increase in CD4 cell counts, and these patients may remain susceptible to opportunistic infections. A group of 13 patients with CD4 cell counts 3 after ⩾9 months of combined antiretroviral treatment received interleukin (IL)–2 immunotherapy (4.5×106 IU twice daily for 5 days every 6 weeks). After only 3 cycles, their CD4 cell counts increased from 123 cells/mm3 (range, 104–134 cells/mm3) to 229 cells/mm3 (range, 176–244 cells/mm3). A marked increase was noted in the naive CD45RA subpopulation of CD4 T lymphocytes. Furthermore, the magnitude of the CD4 cell count response correlated with the baseline expression levels of the antiapoptotic molecule Bcl-2. This study demonstrates that IL-2 immunotherapy can accelerate the recovery of CD4 lymphocytes in persons whose CD4 cell counts fail to increase rapidly in response to combined antiretroviral treatment


  • Open Access

    The First α Helix of Interleukin (Il)-2 Folds as a Homotetramer, Acts as an Agonist of the IL-2 Receptor β Chain, and Induces Lymphokine-Activated Killer Cells

    by Ralph Eckenberg, Thierry Rose, Jean-Louis Moreau, Robert Weil, Franck Gesbert, Sigrid Dubois, Diana Tello, Marc Bossus, Hélène Gras, André Tartar, et al.

    Interleukin (IL)-2 interacts with two types of functional receptors (IL-2Rαβγ and IL-2Rβγ) and acts on a broad range of target cells involved in inflammatory reactions and immune responses. For the first time, we show that a chemically synthesized fragment of the IL-2 sequence can fold into a molecule mimicking the quaternary structure of a hemopoietin. Indeed, peptide p1–30 (containing amino acids 1–30, covering the entire α helix A of IL-2) spontaneously folds into an α-helical homotetramer and stimulates the growth of T cell lines expressing human IL-2Rβ, whereas shorter versions of the peptide lack helical structure and are inactive. We also demonstrate that this neocytokine interacts with a previously undescribed dimeric form of IL-2Rβ. In agreement with its binding to IL-2Rβ, p1–30 activates Shc and p56lck but unlike IL-2, fails to activate Janus kinase (Jak)1, Jak3, and signal transducer and activator of transcription 5 (STAT5). Unexpectedly, we also show that p1–30 activates Tyk2, thus suggesting that IL-2Rβ may bind to different Jaks depending on its oligomerization. At the cellular level, p1–30 induces lymphokine-activated killer (LAK) cells and preferentially activates CD8low lymphocytes and natural killer cells, which constitutively express IL-2Rβ. A significant interferon γ production is also detected after p1–30 stimulation. A mutant form of p1–30 (Asp20→Lys), which is likely unable to induce vascular leak syndrome, remains capable of generating LAK cells, like the original p1–30 peptide. Altogether, our data suggest that p1–30 has therapeutic potential.